Fresenius Medical Care Corporation (FMS) Stock Forecast & Price Target
Fresenius Medical Care Corporation · NYSE
$24.76-0.11 (-0.44%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Fresenius Medical Care Corporation, 0 rate it Buy or better, 0 sit at Hold, and 1 rate it Sell or worse, a moderate sell consensus. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.56 next quarter toward $3.17 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Sell
Strong Buy00%
Buy00%
Hold00%
Sell1100%
Strong Sell00%
Based on 1 analysts giving stock ratings to Fresenius Medical Care Corporation.
As of Jul, 0 of 1 firms rate FMS a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
FMS EPS & revenue forecast
EPS · NEXT QUARTER
$0.56
Range $0.53 – $0.60 · 2 analysts · +3% YoY
Next period, 2 analysts expect Fresenius Medical Care Corporation to earn $0.56 a share (range $0.53 – $0.60), versus $0.55 a year earlier. Full-year consensus is $2.46, growing to $3.17 the year after.
REVENUE · NEXT QUARTER
$4.9B
Range $4.8B – $5.0B · 2 analysts · +1% YoY
Revenue is expected to reach $4.9B (range $4.8B – $5.0B), +1.0% year-over-year. Full-year consensus is $19.5B, rising to $20.2B next year.
Top analysts covering Fresenius Medical Care Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FMS.
#1
DM
David Macdonald
Truist Securities · Rank #67
Hold
$30.00+21.2% to target
Overall win rate
51%
+ Follow
#2
MB
Marianne Bulot
Bank of America Securities
Sell
$22.00-11.1% to target
Coverage
—
+ Follow
#3
GD
Graham Doyle
UBS
Sell
No targeton FMS
Coverage
—
+ Follow
#4
VL
Victoria Lambert
Berenberg Bank
Buy
$34.50+39.3% to target
Coverage
—
+ Follow
#5
LB
Lisa Bedell Clive
Bernstein
Hold
$31.50+27.2% to target
Coverage
—
+ Follow
FMS stock forecast FAQ
Is FMS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Sell. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 0 are Hold, and 1 are Sell or Strong Sell.
How many Wall Street analysts cover FMS?+
1 analysts have an active rating on Fresenius Medical Care Corporation.
Who is the most accurate analyst covering FMS?+
Among analysts who currently cover FMS, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #67). Their current call is Hold with a $30.00 target.
What is Fresenius Medical Care Corporation's projected EPS for next quarter?+
The consensus estimate is $0.56 per share (range $0.53 – $0.60) across 2 analysts. Full-year EPS is projected at $2.46, rising to $3.17 the following year.
How much revenue is Fresenius Medical Care Corporation expected to report next quarter?+
Consensus revenue is $4.9B (range $4.8B – $5.0B). Full-year revenue is projected at $19.5B, growing to $20.2B next year.
Have analysts been upgrading or downgrading FMS lately?+
As of Jul, 0 of 1 firms rate FMS a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FMS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
